Pharmacists revise position on formularies
The Academy of Managed Care Pharmacy, Alexandria, VA, released a revised position statement supporting the appropriate design and use of drug formularies.
The Academy of Managed Care Pharmacy, Alexandria, VA, released a revised position statement supporting the appropriate design and use of drug formularies.
The academy's board of directors adopted the revised position statement in an effort to better inform the public, policy-makers and other health care professionals about the role formularies play in fostering the appropriate and effective use of prescription medications.
"A formulary enhances the quality of care by encouraging the use of those prescription medications that are demonstrated to be safe, effective and produce superior patient outcomes," according to the position statement.
The academy said a formulary works best when it supports and operates in conjunction with other tools that promote quality and optimal results, such as drug utilization review and medical treatment guidelines and prescribing protocols.
"Drug costs are not the overriding factor in determining which drugs to include on the formulary," according to the academy. "Decisions are also based in part on results of clinical trials, scientific studies, evaluation of the drug's role in disease treatment guidelines, comparisons with other like products and data that reflect the drug's actual or projected use in specific patient populations." PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Grants Priority Review to Regeneron’s Eylea for Macular Edema Following Retinal Vein Occlusion
April 18th 2025Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks achieved non-inferior visual acuity outcomes compared to Eylea in patients with macular edema following retinal vein occlusion.
